Mesothelioma.com Resources for Patients and their Families

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Brief Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.

Tracking Information
First Received DateAugust 2, 2017
Last Changed DateAugust 1, 2018
Start DateOctober 2, 2017
Anticipated Primary Completion DateMay 2021
Primary Outcome Measures

Phase 1: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability] [Time Frame: Screening through 60 days after end of treatment, up to 18 months]

Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [Time Frame: Assessed every 8 weeks for 12 months, then every 12 weeks, up to 18 months]

Secondary Outcome Measures

Phase 1 & Phase 2: ORR based on RECIST v1.1 and modified RECIST (mRECIST) [Time Frame: Assessed every 8 weeks for 12 months, then every 12 weeks, up to 18 months]

Phase 1 & Phase 2: Duration of response based on RECIST v1.1 and mRECIST [Time Frame: Assessed every 8 weeks for 12 months, then every 12 weeks, up to 18 months]

Phase 1 & Phase 2: Disease control rate based on RECIST v1.1 and mRECIST [Time Frame: Assessed every 8 weeks for 12 months, then every 12 weeks, up to 18 months]

Phase 1 & Phase 2: Duration of disease control based on RECIST v1.1 and mRECIST [Time Frame: Assessed every 8 weeks for 12 months, then every 12 weeks, up to 18 months]

Phase 1 & Phase 2: Progression-free survival based on RECIST v1.1 and mRECIST [Time Frame: Assessed every 8 weeks for 12 months, then every 12 weeks, up to 18 months]

Phase 1 & Phase 2: Overall survival [Time Frame: At 1 year, 2 years, and end of study, up to 24 months]

Phase 1 & Phase 2: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability] [Time Frame: Screening through 60 days after end of treatment, up to 18 months]

Descriptive Information
PhasePhase 1/Phase 2
Study TypeInterventional
Condition
  • Advanced Malignancies
Intervention
  • Drug: INCAGN01949
  • Drug: Nivolumab
  • Drug: Ipilimumab
  • Drug: INCAGN01949
Study Arms / Comparison Groups3 / 0
Recruitment Information
Recruitment StatusRecruiting
Anticipated Enrollment651
GenderAll
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Contact Incyte Corporation Call Center (US)
Email: medinfo@incyte.com
Phone: 1.855.463.3463
Eligibility Criteria

Inclusion Criteria:

- Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.

- Phase 1: Subjects with advanced or metastatic solid tumors.

- Phase 1: Subjects who have disease progression after treatment with available therapies.

- Phase 2: Subjects with advanced or metastatic gastric cancer, SCCHN, NSCLC, or RCC and are considered refractory to prior PD-1/L1 therapy.

- Presence of measurable disease based on RECIST v1.1.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

Exclusion Criteria:

- Laboratory and medical history parameters not within the Protocol-defined range

- Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.

- Has not recovered to ≤ Grade 1 from toxic effects of prior therapy.

- Active autoimmune disease.

- Known active central nervous system metastases and/or carcinomatous meningitis.

- Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.

- Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.

- Known history of human immunodeficiency virus (HIV); HIV 1/2 antibodies.

Administrative Information
NCTIDNCT03241173
Responsible PartySponsor
SponsorIncyte Biosciences International Sàrl
Verification DateAugust 2018
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

Remembering Sean Sasser: The Real World Star’s AIDS Advocacy Halted by Mesothelioma

Attending the 2018 Minneapolis Mesothelioma Symposium

8 Mesothelioma Myths and Misconceptions

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: